NFE2L2 and familial pancreatic carcinoma: For instance, the PI3K-DNAPK inhibitor PIK-75 was found to promote NRF2 degradation and overcome gemcitabine resistance in pancreatic cancer cells [113], while the Bcl-2 inhibitor venetoclax was shown to suppress the overexpression of NRF2 induced by hypomethylating agents in AML cells, by promoting NRF2 proteasomal degradation through the reinforced interaction with KEAP1, thus triggering mitochondrial ROS generation and apoptosis [114].